Global Fluticasone Propionate Inhalers Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Fluticasone Propionate Inhalers Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks.

Market Overview:

The latest research study on the global Fluticasone Propionate Inhalers market finds that the global Fluticasone Propionate Inhalers market reached a value of USD 3210.89 million in 2022. It’s expected that the market will achieve USD 3519.11 million by 2028, exhibiting a CAGR of 1.54% during the forecast period.

Assessment of the Overall Impact of COVID-19 on the Industry

The impact of COVID-19 on the global economy. More than three million lives have been lost to COVID-19 since the start of 2021 and the toll continues to rise. Many more have suffered a serious illness. Close to 90 million people are expected to fall into extreme deprivation this year. Compared with the IMF report released in June, the global economic contraction in 2020 will not be as severe as previously predicted. This revision reflects a better-than-expected economic recovery in the second quarter. Global growth is projected at 5.2 percent in 2021, a little lower than in the June 2020 WEO Update, reflecting the more moderate downturn projected for 2020 and consistent with expectations of persistent social distancing. This is the worst global recession in decades, despite the huge efforts of governments with the support of fiscal and monetary policies to deal with the economic downturn. But from a long-term perspective, it is expected that the severe recession caused by the pandemic will cause a prolonged economic depression by reducing investment. Should COVID-19 outbreaks persist, should restrictions on movement be extended or reintroduced, or should disruptions to economic activity be prolonged, the recession could be deeper. Businesses might find it hard to service debt, heightened risk aversion could lead to climbing borrowing costs, and bankruptcies and defaults could result in financial crises in many countries. Under such unfavorable circumstances, there will still be a possibility of a global decline in 2021.
Covid-19 forced many unprepared enterprises and processes to digitize at a tortuous speed. Internet has become the foundation of successful economic transformation in Covid-19 era. Integrated services provide a powerful impetus for the Internet and a large number of services to continue to play an economic and social role.
When faced with the fear and pain of Covid-19 outbreak, it is difficult for people to consider certain situations in advance. Business leaders should not only pay attention to how to survive, but also think about how to develop under the background of Covid-19 era, because Covid-19 era is not the past, but a new reality.
Covid-19 has accelerated social and technological changes, and has had an impact on other aspects. This era is a technology-driven era, and people are forced to work from home, retail online, serve entertainment, and accept the trend of telemedicine and machine learning. This change reflects a profound behavioral change, which cannot be realized even within ten years.

Market Development Constraints

For Fluticasone Propionate Inheraler, good brand and terminal maintenance are two important factors for the stable development of Fluticasone Propionate Inheraler. From the comparison between well-known pharmaceutical companies and relatively low pharmaceutical companies in the whole value chain, it can be seen that well-known companies can obtain greater industrial chain profits from channels by virtue of good brand effect; However, companies with low reputation need distributors and terminal outlets to promote sales, and can only give most of their profits to channels and sales terminals, thus becoming cheap manufacturers with reserve prices. The establishment of word of mouth is inseparable from the accumulation of time and continuous advertising investment. At present, the cost of advertising or promotion of various media is getting higher and higher, and the cost of brand building of new products is also getting higher and higher. With the increase of cost, the barriers of original brands are getting higher and higher. At the same time, compared with non-brand companies, brand products currently invest more in advertising every year, which further increases the barriers to brand entry. In addition, in recent years, the policy pressure of the pharmaceutical industry has gradually increased. Drug advertising regulatory policies are becoming stricter, and drug price bidding reduces corporate profits. This further increases the difficulty of building a new brand. This leads to the gradual deepening of brand drug barriers and the decline of value chain. In this case, patients' decision-making power in e-commerce channels is far greater than that in retail pharmacies and hospitals. Well-known drugs have good safety and effectiveness, and patients have high awareness, so they are in a dominant position in the sales of e-commerce drugs. The high barriers of Fluticasone Propionate Inhalers industry will limit the further development of the market to a certain extent, which is not conducive to the development of new entrants.

Region Overview:

From 2023-2028, North America is estimated to witness robust growth prospects.

Company Overview:

GSK, Mylan, Teva, Akorn and West-Ward Pharmaceuticals are the five key players in the global Fluticasone Propionate Inhalers market. These companies have shown consistent growth in revenue, larger volumes of sales and a prominent presence in terms of share in the global Fluticasone Propionate Inhalers market in the past 5 years.

GlaxoSmithKline PLC operates as a research-based pharmaceutical company. The Company develops, manufactures, and markets vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. GlaxoSmithKline provides products for infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer.

Mylan NV is a global generic and specialty pharmaceuticals company. The Company operates an active pharmaceutical ingredient manufacturer and runs a specialty business focused on respiratory, allergy, and psychiatric therapies.

Fluticasone Propionate Inhalers Products launched in 2019.

Segmentation Overview:

Among different product types, 120 Metered Sprays segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Adults segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Fluticasone Propionate Inhalers market covered in Chapter 3:

Teva
Akorn
Mylan
Apotex
West-Ward Pharmaceuticals
Wockhardt
GSK

In Chapter 4 and Chapter 14.2, on the basis of types, the Fluticasone Propionate Inhalers market from 2018 to 2029 is primarily split into:

60 Metered Sprays
120 Metered Sprays
150 Metered Sprays

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Fluticasone Propionate Inhalers market from 2018 to 2029 covers:

Kids
Adults

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)